Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis

Sponsor

Modern Biosciences Ltd (Industry)

Overall Status

Completed

CT.gov ID

NCT02480946

Collaborator

Covance (Industry)

105

Enrollment

Locations

Arms

Duration (Months)

Patients Per Site

1.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments. MBS2320, the drug being tested in this trial, represents a new approach to treating RA, with the potential not only to reduce levels of inflammation but to also directly inhibit bone damage.The aim of this study is to test the safety of MBS2320 in healthy volunteers, to find out how MBS2320 levels change in the blood with dose, and to test the safety and compatibility of giving MBS2320 to patients with RA in combination with an existing treatment, methotrexate.

Condition or Disease	Intervention/Treatment	Phase
Arthritis, Rheumatoid	Drug: MBS2320 Drug: Placebo Drug: Methotrexate	Phase 1

Detailed Description

The study will be conducted in 4 parts (parts A to D). The principal aim of this study is to obtain safety and tolerability data when MBS2320 is administered orally as single and multiple doses to healthy subjects (parts A to C). The effect of MBS2320 on the pharmacokinetics (PK) of the first-line rheumatoid arthritis (RA) therapy, methotrexate (MTX), and the effect of MTX on the PK of MBS2320, will also be evaluated in a cohort consisting of subjects with RA (Part D).

Study Design

Study Type:

Interventional

Actual Enrollment :

105 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double (Participant, Investigator)

Primary Purpose:

Treatment

Official Title:

A Four-Part Phase-1 Study Investigating the Tolerability, Safety and Pharmacokinetics (PK) of MBS2320 in Healthy Subjects and in Subjects With Rheumatoid Arthritis (RA) Also Treated With Methotrexate

Study Start Date :

Jul 1, 2015

Actual Primary Completion Date :

Mar 1, 2017

Actual Study Completion Date :

Mar 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Single Ascending Dose and Food Effect Part A will be a single-dose, sequential-group, double-blind, placebo-controlled study of MBS2320.	Drug: MBS2320 As described in the arm descriptions Drug: Placebo As described in the arm descriptions
Experimental: Multiple Ascending Dose Part B will be a multiple-dose, sequential-group, double-blind, placebo-controlled study to investigate 3 planned dose levels.	Drug: MBS2320 As described in the arm descriptions Drug: Placebo As described in the arm descriptions
Experimental: Relative Bioavailability Part C will be an open-label, randomised, 2-period crossover relative bioavailability study of MBS2320 in capsules or suspension. The intention is to enrol 8 healthy subjects. Each subject will participate in 2 treatment periods.	Drug: MBS2320 As described in the arm descriptions Drug: Placebo As described in the arm descriptions
Experimental: Drug-Drug Interaction with Methotrexate Part D will be a multiple dose study incorporating an open-label, fixed-sequence drug-drug interaction between MBS2320 and methotrexate and biomarker evaluation.	Drug: MBS2320 As described in the arm descriptions Drug: Methotrexate Background therapy as described in the arm descriptions Other Names: Rheumatrex Trexall Amethoperin Mexate

Outcome Measures

Primary Outcome Measures

Safety and tolerability (incidence of all grade adverse events and dose limiting toxicities during the observation period and/or study treatment periods) [Within 7 days]

Secondary Outcome Measures

Study Parts A, B and C - Peak Plasma Concentration (Cmax) of MBS2320 [Part A and C - Up to 72hrs post dose, Part B - Up to 72 hrs post day 14 dose]
Study Parts A, B and C - Area under the plasma concentration versus time curve (AUC) of MBS2320 [Part A and C - Up to 72hrs post dose, Part B - Up to 72 hrs post day 14 dose]
Study Parts A, B and C Time to peak plasma concentration (Tmax) of MBS2320 [Part A and C - Up to 72hrs post dose, Part B - Up to 72 hrs post day 14 dose]
Part D - Peak Plasma Concentration (Cmax) of MBS2320 and methotrexate [During the study treatment period]
Half-life (T1/2)
Part D - Area under the plasma concentration versus time curve (AUC) of MBS2320 and methotrexate [During the study treatment period]
Peak Plasma Concentration (Cmax), Area under the plasma concentration versus time curve (AUC), Time to peak plasma concentration (Tmax), Half-life (T1/2)
Part D - Time to peak plasma concentration (Tmax) of MBS2320 and methotrexate [During the study treatment period]
Part D - Half-life (T1/2) of MBS2320 and methotrexate [During the study treatment period]
Part D - Early response biomarkers of disease activity and bone turnover [Day 1 and 16.]
CRP and CTX

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Principal Inclusion Criteria:

Parts A, B, and C.

Healthy males or females between 18 and 60 years of age.
A body mass index (BMI) between 18.0 and 30.0 kg/m2.
Female subjects will be of non-childbearing potential or postmenopausal as defined by the protocol.
Female subjects must not be pregnant.

Part D

Subjects will be otherwise healthy males or females with a diagnosis of RA between 18 and 70 years of age.
Subjects will have a BMI between 18.0 and 30.0 kg/m2.
Female subjects must not be pregnant.
Subjects must have been treated with, and tolerated, oral or subcutaneous MTX for a minimum of 3 months prior to screening entry.

Principal Exclusion Criteria:

Parts A, B, and C.

Male subjects who do not agree to use appropriate contraception.
Female subjects who are receiving HRT who do not agree to use appropriate contraception.
Subjects who have donated blood in the 3 months, plasma in the 7 days or platelets in the 6 weeks prior to screening.
Subjects who consume more than the permitted alcohol requirement, who have a significant history of alcoholism or drug/chemical abuse.
Subjects who are unwilling to abstain from alcohol as required.
A positive urine drug screen, alcohol breath test at screening or first admission.
Subject has received a live virus vaccination within the 30 days prior to first dose administration.
Subjects with a positive test for tuberculosis.

Additional Part D Exclusions

Subjects who have received any medication (except MTX) known to chronically alter drug absorption or elimination processes within 30 days prior to the first dose administration.
Subjects currently taking any medications other than those allowed per protocol guidelines.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Covance Royal Liverpool Clinical Research Unit,Royal Liverpool University Hospital	Liverpool	Merseyside	United Kingdom	L7 8XP
2	Covance Clinical Research Unit Ltd.	Leeds	West Yorkshire	United Kingdom	LS2 9LH
3	NIHR/Wellcome Trust Imperial Clinical Research Facility (CRF)	London		United Kingdom	W12 0HS